Enhancement of Adenoviral Oncolytic Activity by Modification of the E1A Gene Product
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
prostate cancer
Modality
Gene Therapy
Mechanism
oncolytic adenovirus (E1A modification)
Target
androgen receptor
rNPV Envelope
Low
-$36.6M
costs +25% · peak −25%
Base
-$29.1M
cumulative PoS 0.6%
High
-$21.7M
costs −25% · peak +25%
This is an illustrative oncolytic adenovirus envelope for cohort consistency only. The patent is expired and the asset is an old E1A/AR prostate-selective method, so PoS is reduced versus active clinical adenoviral programs.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.50
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.572 — composite-score rank #40 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#18) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
E1A/androgen-receptor chimeric prostate-selective adenovirus
The direct asset: a target-cell-specific replication-competent adenovirus using prostate-specific transcriptional control and modified E1A/AR biology for selective cytotoxicity.
Criteria 1 and 2: exact modality and indication; old platform with expired patent.
CAN-2409 / ProstAtak
Adjacent prostate adenoviral clinical archetype. It is not E1A-modified CRAd, but it anchors contemporary prostate adenoviral development.
Criteria 2 and 4: same organ and viral platform family, different vector design.
Oncorine / H101
Approved oncolytic adenovirus precedent; useful as a regulatory archetype but far from prostate-selective E1A/AR design.
Criteria 3 and 4: approved oncolytic adenovirus archetype only.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $14.0M | 24 mo | 26.0% | [0] |
| Phase I | $50.0M | 18 mo | 50.0% | [0] [1] |
| Phase II | $110.0M | 30 mo | 18.0% | [1] [2] |
| Phase III | $230.0M | 42 mo | 34.0% | [1] [2] |
| NDA/BLA Review | $15.0M | 12 mo | 80.0% | [2] |
Multiplier handling: No multipliers eligible for this asset under the locked methodology. See methodology for the rule.
Peak revenue and discount rate
$75.0M peak · WACC 16.0%
Peak revenue. With expired IP and no active product, only a low illustrative value is defensible. The $75M figure reflects possible historical/academic platform value, not a proprietary prostate adenovirus revenue forecast.
WACC. Expired, old, preclinical oncolytic adenovirus IP has very high commercial and translational risk.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$29.1M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$114.9M
P25
-$30.1M
P50 (median)
-$12.6M
P75
-$7.7M
P95
-$4.6M
Prob ≥ 0
0.0%
Evidence register
3 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is E1A-modified prostate-selective oncolytic adenovirus with expired patent cmo_findings.asset_class_reality | Enhancement of Adenoviral Oncolytic Activity by Modification of the E1A Gene Product regulatory | 2014-10-07 | high |
Prostate adenoviral clinical archetype comparators[1] | Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer trial_disclosure | 2025-01-01 | high |
Approved oncolytic adenovirus archetype comparators[2] | Oncorine, the World First Oncolytic Virus Medicine and its Update in China peer_review | 2017-11-01 | high |
Thesis
Why this asset earns its rank
This is an old oncolytic adenovirus method, not a fundable gene-therapy product. The JHU technology modifies the E1A gene product in a prostate-selective replication-competent adenovirus, using androgen-receptor/prostate-specific transcriptional control to drive cytotoxicity. The listed patent is expired. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial.
The comparator set is purely archetypal. CAN-2409 shows that prostate adenoviral immunotherapy can still be clinically relevant, while Oncorine shows narrow adenoviral approval precedent, but neither revives an expired E1A/AR prostate CRAd patent. The engine result is -$36.6M to -$21.7M, with a base rNPV of -$29.1M and cumulative PoS of 0.6%; that low placeholder is appropriate for old, expired, non-active IP.
Verdict: scientifically coherent but commercially exhausted. It earns its rank from prostate relevance and the gene_therapy bucket, while a CMO would immediately flag expired patent status, old-vector design, and the absence of a current development sponsor.
Key risks
Asset-specific, not generic biotech risks
- Expired IP: the US patent listed by JHU expired in 2023, limiting any standalone licensing value.
- Modality mismatch: this is an oncolytic adenovirus design, not conventional gene therapy.
- Clinical relevance gap: no active E1A/AR prostate CRAd product is identified from the asset file.
- Modern competition: prostate cancer standards have evolved substantially since the 2002 invention date.